With EMPACT-MI being presented at ACC, the definitive study of an additional agent (empagliflozin) will allow for a great discussion on options for patients who have acute MI and evidence of heart failure.

In this interview, Schuyler Jones, MD FACC, and Purvi Parwani, MBBS, MPH, FACC discuss Not the Same Old 5 Medications: Contemporary GDMT Algorithm in the Post-MI Patient.

Related References:

1. Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., Solomon, S. D., Steg, P. G., Berwanger, O., Cikes, M., De Pasquale, C. G., East, C., Fernandez, A., Jering, K., Landmesser, U., Mehran, R., Merkely, B., … PARADISE-MI Investigators and Committees (2021). Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. The New England journal of medicine, 385(20), 1845–1855. https://doi.org/10.1056/NEJMoa2104508
2. Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., & Butler, J. (2022). Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American heart journal, 253, 86–98. https://doi.org/10.1016/j.ahj.2022.05.010
3. James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Eriksson, N., Andersen, K., Austin, D., Arefalk, G., Carrick, D., Hofmann, R., Hoole, S. P., Jones, D. A., Lee, K., Tygesen, H., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Parvaresh Rizi, E., Deanfield, J., … Oldgren, J. (2024). Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM evidence, 3(2), EVIDoa2300286. https://doi.org/10.1056/EVIDoa2300286